Biopharmaceutical News and Research

RSS

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business.

25 Aug 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer.

24 Aug 2009

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders.

24 Aug 2009

Profibrix raises funds for clinical and preclinical development

ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company's Supervisory Board.

24 Aug 2009

Poniard Pharmaceuticals may sell up to $60 million of its registered common stock to finance its picoplatin clinical development and commercialization programs

...

20 Aug 2009

John R. Walsh to be responsible for continued expansion of IMS' payer and government solution initiatives

IMS Health today announced that John R. Walsh has been named senior vice president, Payer and Government Solutions, a new position. Previously, Walsh was senior vice president, Strategy and Business Development for IMS. He continues to report to David R. Carlucci, IMS chairman and CEO, and will be based in Norwalk, CT.

20 Aug 2009

Orient Pharma granted commercialization rights for a drug candidate by DURECT

DURECT Corporation today announced that it has signed a development and license agreement with Orient Pharma Co., Ltd., a diversified multinational pharmaceutical, healthcare and consumer products company with headquarters in Taiwan, under which DURECT has granted to Orient Pharma development and commercialization rights in selected Asian and South Pacific countries to a drug candidate based on DURECT's ORADUR(R) Technology and one specified active pharmaceutical ingredient for the treatment of attention deficit hyperactivity disorder (ADHD).

19 Aug 2009

Synco Bio to manufacture Versartis type 2 diabetes drug candidate

SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel GLP-1 analog for monthly dosing to treat type 2 diabetes Under the agreement, SynCo will further develop the Versartis existing production process for VRS-859 and optimize the manufacturing process to increase yields for the forthcoming cGMP production.

18 Aug 2009

Biospecifics Technologies reports Q2 2009 financials

BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the second quarter ended June 30, 2009.

12 Aug 2009

Forest Labs and Astrazeneca to co-develop and commercialize ceftaroline

Forest Laboratories (NYSE:FRX) and AstraZeneca (NYSE:AZN) announced today they have entered into a definitive collaboration agreement to co-develop and commercialize ceftaroline in all markets outside the United States, Canada and Japan.

12 Aug 2009

Inhibitex reports Q2 2009 financials

Inhibitex, Inc. (Nasdaq: INHX), today announced its financial results for the second quarter ended June 30, 2009. The Company held cash, cash equivalents and short-term investments of $24.5 million at June 30, 2009, as compared to $33.1 million at December 31, 2008.

12 Aug 2009

VIVUS reports Q2 2009 financials

VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the second quarter ended June 30, 2009.

11 Aug 2009

Bill Clinton, Pfizer, and Mylan announce new agreements to lower prices of antiretrovirals for HIV/AIDS in the developing world

President Bill Clinton announced two important and complementary agreements today to enable better, more affordable treatments for patients on second-line antiretroviral (ARV) therapy for HIV/AIDS in the developing world.

6 Aug 2009

Innexus Biotechnology announces business development initiative on lead preclinical candidate

InNexus Biotechnology Inc. announced today that the Company will embark on a business development initiative for DXL625™ (CD20), the Company’s lead preclinical candidate for the prospective treatment of Non-Hodgkin’s Lymphoma and/or Chronic Lymphocytic Leukemia.

6 Aug 2009

Accelerating the development of new cancer drugs

A phase I clinical trial enrolled its first patient only two days after U.S. Food and Drug Administration clearance of the experimental drug for a first-in-human cancer trial, a milestone that normally takes three to six months. Investigators from The University of Texas M. D. Anderson Cancer Center and pharmaceutical company AstraZeneca have reported their work in the Journal of Clinical Oncology published online on August 3rd.

4 Aug 2009

Schering-Plough starts patient enrollment in phase 3 trial for Acadesine

Schering-Plough Corporation today announced the start of patient enrollment in RED-CABG, the Phase 3 Trial for acadesine, an investigational, potentially first-in-class adenosine regulating agent (ARA). Acadesine was licensed from PeriCor Therapeutics, Inc., a privately held specialty biopharmaceutical company.

12 May 2009

Biopharmaceutical News and Research

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Profibrix raises funds for clinical and preclinical development

Poniard Pharmaceuticals may sell up to $60 million of its registered common stock to finance its picoplatin clinical development and commercialization programs

John R. Walsh to be responsible for continued expansion of IMS' payer and government solution initiatives

Orient Pharma granted commercialization rights for a drug candidate by DURECT

Synco Bio to manufacture Versartis type 2 diabetes drug candidate

Biospecifics Technologies reports Q2 2009 financials

Forest Labs and Astrazeneca to co-develop and commercialize ceftaroline

Inhibitex reports Q2 2009 financials

VIVUS reports Q2 2009 financials

Bill Clinton, Pfizer, and Mylan announce new agreements to lower prices of antiretrovirals for HIV/AIDS in the developing world

Innexus Biotechnology announces business development initiative on lead preclinical candidate

Accelerating the development of new cancer drugs

Schering-Plough starts patient enrollment in phase 3 trial for Acadesine

Serentis begins trial with first-in-class SRD441 for eczema

Experimental drug lowers PSA levels

Stem cells from bone marrow used to grow new blood vessels

Event guide: 3rd EHS for Biopharma Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News